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Abstract
Solid tumors have a raised interstitial fluid pressure (IFP) due to high vessel permeability, low lymphatic drainage,
poor perfusion, and high cell density around the blood vessels. To investigate tumor IFP as an early-response bio-
marker, we have tested the effect of seven anticancer chemotherapeutics including cytotoxics and targeted cyto-
statics in 13 experimental tumor models. IFP was recorded with the wick-in-needle method. Models were either
ectopic or orthotopic and included mouse and rat syngeneic as well as human xenografts in nude mice. The mean
basal IFP was between 4.4 and 15.2 mmHg; IFP was lowest in human tumor xenografts and highest in rat syngeneic
models. Where measured, basal IFP correlated positively with relative tumor blood volume (rTBV) determined by
dynamic contrast-enhanced magnetic resonance imaging. Most chemotherapeutics sooner (2 or 3 days) or later
(6 or 7 days) lowered tumor IFP significantly, and the cytotoxic patupilone caused the greatest decrease in IFP. In
rat mammary orthotopic BN472 tumors, significant drug-induced decreases in IFP and rTBV correlated positively
with each other for both patupilone and the cytostatic vatalanib. In the two orthotopic models studied, early de-
creases in IFP were significantly (P ≤ .005) correlated with late changes in tumor volume. Thus, drug-induced de-
creases in tumor IFP are an early marker of response to therapy, which could aid clinical development.
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Introduction
The initial growth of a solid tumor makes use of existing vasculature,
but further growth requires formation of new blood vessels, that is,
angiogenesis, and these blood vessels tend to be leaky, highly irregular,
and tortuous and exhibit a low blood flow [1,2]. Compression of the
blood vessels by proliferating cells also increases the microvascular pres-
sure, and an inadequate lymphatic system limits drainage of excess
fluid and thus reduces fluid movement through the interstitium. To-
gether, these factors cause an elevated interstitial fluid pressure (IFP) in
solid tumors compared with normal tissues [1]. In experimental tumor
models, IFP is uniform across the whole tumor except at the periphery
where it drops precipitously [1]. In the clinic, a raised IFP has been
demonstrated in several tumor types [1], although data from cervical
tumors indicated much greater heterogeneity than in experimental
models [3].
IFP has been used as a prognostic factor where it was shown to be
the single best indicator of survival for patients with cancer of the
cervix [3]. Furthermore, chemotherapy has been shown to reduce
IFP. Preclinically, this has been shown for dexamethasone [4], hydral-
azine [5], imatinib [6], PGE1 [7], and patupilone [8]. In the latter
study, decreases in IFP were negatively correlated with apoptosis (P <
.001) and positively correlated with tumor blood volume (P =
.0005). In the clinic, bevacizumab [9] and paclitaxel [10] have been
shown to reduce the IFP of rectal and breast tumors, respectively.
However, whether the drug-induced decrease in IFP is, in general,
predictive of subsequent response has not been investigated. This
could be very useful because generic markers of tumor response
can allow optimization of 1) current therapies, for example, discon-
tinuation in the event of a lack of response and 2) new drugs in de-
velopment, for example, attainment of an optimal biologic dose that
provides an alternative to the maximum tolerated dose. Although
measurement of IFP is invasive, it has been used in the clinic for
breast, cervix, colorectal, head and neck, lung, melanoma, and renal
tumors [1,3,9,10].
Abbreviations: rTBV, relative tumor blood volume; DCE-MRI, dynamic contrast-
enhanced magnetic resonance imaging; IFP, interstitial fluid pressure; TVol, tumor volume
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The aim of this study was to investigate 1) the relationship be-
tween IFP and the tumor vasculature and 2) the effects of several
different chemotherapeutics, including cytotoxics and cytostatic tar-
geted agents on IFP to better understand the nature of IFP and
whether it could be a marker of tumor response to chemotherapy.
Materials and Methods
Animals
All animal experiments were done in strict adherence to the Swiss
law for animal protection. Female C3H/He, black C57BL/6, HsdEZ
nu/nu (Harlan nude), and BALB/c nude mice were obtained from Iffa
Credo (Charles River, St Germain Sur L Arbresle, France) or Novartis
(Basel, Switzerland). Female BDIX and Brown-Norwegian (BN) rats
were obtained from Charles Rivers or Harlan Netherlands BV (Horst,
Netherlands). Nudemicewere kept in a pathogen-controlled environment.
Tumor Models
Cell culture materials were obtained from Life Technologies (Paisley,
United Kingdom) or BioConcept (Allschwil, Switzerland).
Orthotopic tumor models. BN472 rat mammary carcinomas were
established in female BN rats by orthotopic (mammary fat pad) trans-
plantation of BN472 tumor fragments obtained from donor rats [8].
B16/BL6 mice melanoma cells were injected intradermally (ID) in the
ear from where they rapidly metastasize to the lymph nodes, primarily
at the neck, and these LN-mets were studied in this report [11]. RIF-1
mice fibrosarcoma tumors were induced by concentrating 2 to 5 × 106
cells in 100 μl of Hank’s balanced salt solution and injecting subcuta-
neously (SC) in the top of the right thigh of C3H/He mice [12].
Ectopic tumor models. PROb rat colon adenocarcinoma cells (a.k.a.
DHD/K12/TrB) were a gift from the laboratory of Chandra Rubin,
Uppsala, Sweden. They were cultured in Dulbecco’s modified Eagle
medium (DMEM) + F10 medium with the addition of 2 mM glu-
tamine and 10% fetal calf serum (FCS). U87MG human glioma cells
were cultured in DMEM high glucose supplemented with 10% FCS,
1% glutamine. 1A9 [13] and 1A9ptx10 paclitaxel-resistant variant [14]
human ovarian carcinoma cells were cultured in RPMI-1640 medium
supplemented with 20% FCS and 1% glutamine. For the culture of
1A9ptx10 cells, this mediumwas supplemented with 17.5 nM paclitaxel
and 5 μg/ml verapamil. C6 rat glioma cells were cultured in RPMI-1640
supplemented with 10% FCS and 1% glutamine. HeLa human cer-
vical adenocarcinoma cells were cultured in DMEM low glucose sup-
plemented with 10% FCS and 1% glutamine. All the tumors were
induced by concentrating 5 × 106 to 107 cells in 100 μl of phosphate-
buffered saline and injecting SC in the right flank of Harlan nude mice
or, in some cases, of BALB/c (C6 cells) or BDIX rats (PROb cells).
Drug Preparation and Treatment
Animals were randomized into different treatment groups based on
tumor size (200-400 mm3 in mice; 500-1000 mm3 in rats). IFP mea-
surements were made in each individual animal immediately before
treatment and at days 2 to 3 and days 6 to 7 after initiation of treatment
(when applicable, treatment occurred 2 hours before the second or third
IFP measurement).
Patupilone (EPO906), imatinib (STI571), vatalanib (PTK/ZK),
everolimus (RAD001), and AEE788 were obtained from Chemical
Development, Novartis, and the powders were stored at +4°C. Cyclo-
phosphamide (CP) and gemcitabine were obtained from Sigma-
Aldrich Chemie, GmbH, (Buchs SG, Switzerland) and Lilly SA
(Fegersheim, France), respectively. All the drugs were freshly prepared
on each treatment day by using the appropriate formulation. The doses
and schedules used in the experiments described in the next paragraphs
were selected based on previous experience with the compounds that
gave significant inhibition of tumor growth but were tolerated by the
animals [8,11,12,15–19]. In general, cytostatics were very well toler-
ated and caused little or no change in body weight (BW), although
the cytotoxics induced BW loss, but at the doses and schedules used,
this was tolerated and normally transient (2-3 days). Animals showing
an individual BW loss more than 15% or with ulcerating tumors or
altered behavior (self-mutilation, immobile) were culled.
Cytostatics. All cytostatics were administered by oral gavage using
5 ml/kg for rats and 10 ml/kg for mice. Imatinib is an inhibitor of
Bcr-Abl, c-kit, and the platelet-derived growth factor receptor; it was
administered at 50 to 200 mg/kg daily or twice daily for 3 or 7 days.
Vatalanib is a pan–vascular endothelial growth factor receptor
(VEGFR) and platelet-derived growth factor receptor inhibitor; it
was administered at 30 to 200 mg/kg daily. Everolimus is a mamma-
lian target of rapamycin inhibitor; it was administered at 5 mg/kg
thrice weekly or daily. NVP-AEE788 is an inhibitor of VEGFR-2 (kdr)
and epidermal growth factor receptor; it was administered at 30 or
60 mg/kg thrice weekly.
Cytotoxics. Patupilone is a microtubule stabilizer; it was adminis-
tered intravenously (IV) once at 0.15 to 1.5 and 1 to 4 mg/kg for rats
and mice, respectively, using 2 ml/kg for rats and 5 ml/kg for mice.
Gemcitabine is an antimetabolite; it was administered intraperitoneally
(10 ml/kg) at 75 mg/kg twice weekly or 150 mg/kg once weekly. CP is
an alkylating agent; it was administered at 50 and 150 mg/kg (10 ml/kg)
for rats and mice, respectively.
Efficacy and IFP
Tumor volume (TVol) was determined from the formula: l × w ×
h × π / 6. Efficacy was quantified as the T/CTVol determined from the
mean difference in TVol (ΔTVol) of drug-treated animals divided by
the mean difference in volume of vehicle-treated animals.
Tumor IFP was measured using the wick-in-needle technique [15] in
anesthetized animals (1.5%-2.5% isoflurane delivered at 1-2 L/min)
lying on an electrically warmed pad. A standard 30-gauge needle
connected to a pressure transducer was inserted into the central part
of the tumors, and the pressure was monitored for a period of 10 min-
utes. This setup enabled continuous and stable recordings of fluid
pressure at one site in the tumor. Previous measurements have shown
that, in experimental tumors, the IFP is uniform except at the edge [1].
We were able to confirm this in our BN472 tumor model where two
widely separated sites gave IFP values that differed by approximately
5%. In all models, the response to drug treatment was expressed as a
T/CIFP determined from the mean fractional change in IFP (IFP-F) of
drug-treated animals divided by the IFP-F of vehicle-treated animals.
Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Animals were anesthetized using 1.5% isoflurane (Abbott, Cham,
Switzerland) in a 1:1 mixture of O2/N2 and placed on an electrically
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warmed pad for cannulation of one lateral tail vein as previously
described [11]. Magnetic resonance imaging (MRI) experiments were
performed on a Bruker DBX 47/30 or Avance 2 spectrometer (Bruker
Medical, Fällanden, Switzerland) at 4.7 Tequipped with a self-shielded
12-cm bore gradient system. The iron oxide particle intravascular con-
trast agent Endorem was injected (6 mmol of iron per kilogram) for
determining the relative tumor blood volume (rTBV) and an index
of blood flow (BFI). The Endorem uptake curve was fitted with a
sigmoid curve (software: BioMap based in IDL, Research Systems,
Inc, Boulder, CO) to provide a value for the rTBV (plateau) and the
BFI, which was the rTBV divided by the steepest part of the slope.
Note that the line slope for Endorem uptake was very rapid, meaning
the measurement of BFI was less precise than rTBV. Values shown in
the Results section are in arbitrary units, and the principles behind mea-
surement of these parameters have been fully described [11]. At the end
of all experiments, animals were killed by CO2 inhalation.
Histology
Blood vessels. Perfused blood vessels were visualized in frozen sec-
tions of tumor tissue using the nuclear staining dye H33342, which
was injected IV (20 mg/kg, 10 ml/kg) in the lateral tail vein 45 sec-
onds before killing the rodent [11]. Tumors were ablated, embedded
in Tissue-Tek (Sakura, the Netherlands), and frozen slowly on dry
ice. Cryosections of embedded tissue with a thickness of 10 μm were
taken from the central tumor region. Blood vessel outlines were iden-
tified by the surrounding halo of fluorescent H33342-labeled cells. For
measuring vessel density, all vessels, independent of size, were counted
over the whole tumor section, and this was expressed as vessels per
squared millimeters. Vessel sizes reported are external diameters.
Hypoxia
Tumor hypoxia was assessed quantitatively by use of the hydroxyprobe-
1 assay kit, HP-100 (Chemicon International, Billerica, MA). Before
culling (90 minutes), pimonidazole hydrochloride was injected IV
(20 mg/kg, 2 ml/kg) in the lateral tail vein of rodents. The tumor
was removed and embedded in Tissue-Tek and prepared for histology
as previously described. Hypoxia was visualized by detection of bound
pimonidazole using the antipimonidazole monoclonal antibody at a
dilution of 1:50 according to the kit instructions. Microscopic analysis
was performed at amagnification of ×100. Thewhole area of each tumor
slice was photographed, and both hypoxic and nonhypoxic areas were
quantified pixel by pixel and expressed as the percentage hypoxic area
of the tumor total area.
Statistical Analysis
The data are expressed as means ± SEM. The statistical significance
of differences between changes in drug-treated groups and vehicle-treated
groups at a specific time point was determined by using a 2-tailed t-test
or one-way analysis of variance (ANOVA) with Tukey test post hoc for
multiple comparisons (using the software from SigmaStat version 3.1,
Systat Software, Chicago, IL). To quantify the relationship between var-
ious parameters, the Pearson linear correlation coefficient was used to pro-
vide the coefficient of determination, r2, and the associated P value. In the
data sets of BN472 tumors treated with 1) vehicle or vatalanib and 2)
vehicle or patupilone, one rat was excluded from all analyses in each set
because it was an outlier by Grubb’s test for the BFI-F and IFP-F data,
respectively, on day 2 (see http://www.graphpad.com). For all statistical
evaluations, a probability value of P < .05was considered to be significant.
Results
Basal IFP of Ectopic and Orthotopic Tumor Models
Tumor IFP (mm Hg) was evaluated in a wide range of experimental
tumor models (n = 13) including human tumors in nudemice as well as
syngeneic models in mice and rats (Table 1). The highest mean IFPs
were all associated with rat tumors whether grown in mice or rats SC
or orthotopically. Rat colon PROb tumors implanted SC (ectopically)
in rats had an IFP of 15.2 ± 0.7 mm Hg, (n = 45), whereas the same
tumor also implanted SC in the flank of nude mice had a significantly
(P = .01) lower IFP (10.5 ± 2.3 mmHg, n = 14). In contrast, the IFP of
C6 tumors was not significantly altered when grown SC in two differ-
ent types of nude mouse (Harlan or BALB/c). Similarly, when BN472
(in rats) and B16/BL6 (in mice) tumors were grown both SC and
orthotopically in the same animal, there was no significant difference
in IFP (Table 1, P > .7). The human ovarian xenograft 1A9 (wild type)
and its paclitaxel-resistant counterpart (1A9ptx10), which differed only
by one amino acid in β-tubulin, also had no significant difference in
IFP. In general, most human tumor SC xenografts had rather low IFPs
and, in some cases, for example, U87MG, there were several tumors
that were almost unmeasurable, with IFPs less than 2.0 mm Hg. Col-
lectively, these observations emphasize the important role of both the
tumor type and the host species in contributing to the basal IFP.
Effect of Cytostatics on IFP and Tumor Growth
Imatinib. Daily treatment (100 mg/kg) for 1 week of BDIX rats
bearing rat PROb tumors significantly inhibited growth (T/CTVol =
0.32 on day 7) and showed a trend to reduce IFP by approximately
20% with no evidence that longer treatment had greater effects on
IFP (Table 2). A 3-day experiment incorporated dynamic contrast-
enhanced MRI (DCE-MRI) for the measurement of rTBV and BFI
and histology ex vivo for the measurements of hypoxia (Figure 1). Basal
IFP was positively correlated with basal rTBV (r2 = 0.34, P = .06) but
not at all with BFI (r2 = 0.03, P = .7), see Figure 1A. This experiment
confirmed a small but significant decrease (−22%) in IFP (Figure 1B)
and trends for decreases in rTBVand BFI (Figure 1C). Histologic diag-
nosis showed that imatinib also had no significant effect on hypoxia:
T/Cpimo = 0.8, P = .2 (Figure 1D). The same tumors grown in Harlan
nude mice showed much greater decreases in IFP (−85%), although
Table 1. Basal IFP in Function of the Type of Tumor and the Host.
Tumor Model Species Injection Site Host and Strain n IFP
PROb, colon Rat SC BDIX rat 45 15.2 ± 0.7
C6, glioma Rat SC Harlan nude mice 36 14.6 ± 1.5
C6, glioma Rat SC BALB/c nude mice 35 13.7 ± 1.6
BN472, breast Rat SC BN rat 12 13.1 ± 5.4
BN472, breast Rat Mammary gland BN rat 218 12.3 ± 0.3
HeLa, cervical Human SC Harlan nude mice 15 11.2 ± 1.5
PROb, colon Rat SC Harlan nude mice 14 10.5 ± 2.3*
1A9, ovarian Human SC Harlan nude mice 62 7.2 ± 0.6
B16/BL6, melanoma Mouse ID C57BL/6 mice 35 6.7 ± 0.5
B16/BL6 melanoma Mouse SC C57BL/6 mice 14 6.3 ± 3.3
RIF-1, fibrosarcoma Mouse SC C3H/He mice 29 6.3 ± 0.6
1A9ptx10, ovarian Human SC Harlan nude mice 65 6.2 ± 0.5
U87, glioma Human SC Harlan nude mice 24 4.4 ± 0.7
Tumor initiation is described in the Materials and Methods section; they were studied 2 to 7 weeks
after cell injection/transplantation, and IFP (mm Hg) was measured using the wick-in-needle
method. Results show the mean ± SEM for basal IFP of all the tumor models used for experiments
and the number of animals (n).
*P = .01, compared with the same tumor grown in BDIX rats.
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Figure 1. Effects of imatinib and vatalanib on the IFP and vasculature of rat syngeneic tumors. PROb tumors in BDIX rats (A–D) and
BN472 rat mammary carcinomas in BN rats (E–H) were created as described in the Materials and Methods section. After 3 to 7 weeks of
growth, IFP was determined, followed by DCE-MRI measurement of rTBV and BFI using the intravascular contrast agent Endorem be-
fore (day 0) and 3 days after initiation of treatment with vehicle or imatinib (100 mg/kg daily; A–D) or vatalanib (100 mg/kg daily; E–H).
After measurements in situ on day 3, the rats treated with imatinib were injected with pimonidazole, killed 90 minutes later, and the
tumors were ablated for histologic diagnosis. Results show the Pearson correlation for individual tumors between basal rTBV and IFP in
PROb (A) and BN472 tumors (E) and the IFP-F and rTBV-F on day 3 for treatment with vatalanib in BN472 tumors (H) and also the median
and 25th and 75th quartiles for the effect of treatment on the different parameters of IFP-F, rTBV-F, BFI-F, and percentage hypoxia,
where *P < .05 and **P < .01.
Table 2. Effect of Cytostatics on the Growth and IFP of Several Tumor Models.
Treatment Dose (mg/kg) and Schedule Tumor Host n Day 2/3 Day 6/7
T/CIFP T/CTVol T/CIFP
Imatinib 100, daily BDIX rat 6 0.78 0.32* 0.80
12 0.72* — —
PROb 7 0.50† 1.14 0.15‡
Harlan nude mouse 12 0.56‡ — —
C6 BALB/c nude mouse 11 0.85 — —
Vatalanib 100, daily PROb BDIX rat 6 0.91 0.26§ 0.84
200, daily BN472 BN rat 5 0.66† 0.3† 0.5‡
AEE788 60, thrice weekly 12 0.48§ 0.48‡ 0.59‡
Everolimus 5, thrice weekly 10 0.88 0.56 0.75‡
Tumor initiation is described in the Materials and Methods section; after 2 to 7 weeks of growth, IFP was determined before (day 0), during (day 2 or 3), and after treatment (day 6 or 7) with imatinib,
vatalanib, AEE788, or everolimus at the doses and schedules shown. Results show the effect of one dose for each drug in a specific tumor model as the T/C for TVol and IFP.
*P < .01, significantly different from the change in the vehicle.
†The T/C was low but not significantly different to the change in the vehicle (P < .3; 2-tailed t-test or one-way ANOVA with Tukey test post hoc).
‡P < .05, significantly different from the change in the vehicle.
§P < .001, significantly different from the change in the vehicle.
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there was no effect on tumor growth. Thus, the effects of imatinib on
rat PROb tumors seemed to be host-dependent. To a certain extent,
similar data were obtained with C6 tumors, where a significant decrease
(−44%) was detectable when Harlan nude mice were the host but not
with BALB/c nude mice (Table 2). These experiments with imatinib
further emphasize the role of the host vasculature in contributing to
tumor IFP and the effect of treatment on IFP.
Vatalanib. Vatalanib was also tested in the PROb model using
BDIX rats and, despite strongly inhibiting growth, did not significantly
affect IFP (Table 2). Vatalanib was tested at several doses in the BN472
model and showed a dose-dependent reduction of IFP and tumor
growth, and these two effects were significantly correlated (Figure 2).
One experiment is summarized in Table 2. In another experiment,
tumor IFP, rTBV, and BFI were measured in the same mice treated with
vehicle or vatalanib. These data showed that basal IFP was positively
correlated with basal rTBV (Figure 1E) and, to a similar extent, with
BFI (r2 = 0.19, P = .04). Treatment with vatalanib decreased IFP
(Figure 1F ) and also rTBV but did not affect BFI, which, overall,
was unchanged in both treatment groups (Figure 1G). The fractional
changes in rTBV induced by vatalanib correlated significantly with
IFP (Figure 1H) but not with BFI (r2 = 0.19, P = .21). These changes
in noninvasive measurements of vasculature were not associated with
histologic changes in blood vessel density (14.2 ± 1.6 to 16.1 ± 1.9
vessels per mm2, P = .46) but were associated with narrower vessels
(20.8 ± 1.3 μm reduced to 17.7 ± 1.0 μm, P = .07). Finally, overall,
in BN472 tumors, there was a significant positive correlation between
early IFP changes and the eventual change in TVol in response to
vatalanib (r2 = 0.37, P = .0006, n = 28; Figure 3A). These experiments
with vatalanib further demonstrate the relationship between IFP and
the host vasculature, in particular, rTBV, which consistently correlated
with basal IFP and changes in IFP in response to treatment.
AEE788 and everolimus on BN472 tumors. AEE788 (60 mg/kg
thrice weekly) significantly inhibited tumor growth (T/CTVol = 0.48
on day 7) and reduced IFP to a similar degree during the same period
(T/CIFP = 0.48 and 0.59 on days 3 and 7, respectively; Table 2). Similar
data were obtained using a lower dose of 30mg/kg: T/CTVol day 7 = 0.60
and T/CIFP day 7 = 0.47.
As previously reported [20], everolimus (5 mg/kg thrice weekly)
also decreased BN472 tumor growth and IFP, but in both cases, this
was only after a week of treatment probably because this model is not
very sensitive to everolimus (Table 2).
Thus, these further experiments with the BN472 model confirmed a
consistent relationship between drug-induced changes in IFP and inhi-
bition of tumor growth.
Effect of Cytotoxic Drugs on IFP and Tumor Growth
Patupilone. Patupilone was tested in several different ectopic and
orthotopic tumor models (Table 3). The drug potently inhibited
growth and decreased IFP of all tumors with significant effects nor-
mally detectable after 3 to 7 days (max T/CTVol = −0.2 to 0.3 and max
T/CIFP = 0.2-0.5). The exception was the U87 tumor model where
the greatest antitumor effect was only attained on day 7 (T/CTVol =
0.37), and this did not reach significance (P = .14). Consistent with this,
there was also no significant change in the IFP of U87 tumors at either
time point. In BN472 tumors, a dose-dependent effect on IFP was ap-
parent, and there was a highly significant positive correlation between
early IFP changes and the eventual change in TVolday 7 (r
2 = 0.33,
P < .0001; Figure 3B). In RIF-1 tumors, there was also a significant
positive correlation between early IFP changes and the eventual change
in TVolday 7 (r
2 = 0.46, P = .005; Figure 3C ).
Thus, in general, for patupilone, across all models, a drug-induced
decrease in IFP was paralleled by decreases in TVol.
CP and gemcitabine. CP was tested in the two orthotopic tumor
models RIF-1 and BN472. In both models, CP had a rapid inhi-
bitory effect on tumor growth inducing stasis or even minor regres-
sion (Table 3). In contrast, rapid effects on IFP were not significant
(T/CIFP day 3 = 0.78-0.80) and only in BN472 tumors was there a
significant effect after 7 days of treatment (T/CIFP = 0.65, P < .05).
Consequently, there was a significant correlation between IFP-Fday 7
with TVolday 7 (r
2 = 0.41, P = .008) in the BN472 model but not
in the RIF-1 model (Table 4). In a separate study, DCE-MRI studies
showed that in RIF-1 tumors, CP actually increased tumor rTBV:
T/CrTBV on days 3 and 7 was 1.56 and 1.43, respectively, which
may explain the minimal effects of CP on the IFP of RIF-1 tumors.
The antimetabolite gemcitabine was also tested in the BN472 model.
A schedule of 150 mg/kg once weekly showed similar potency to
CP causing TVol stasis after 2 to 7 days; IFP was significantly lowered
after 2 days (T/CIFP = 0.51, P = .03) and returned to baseline by day 7
Figure 2. Dose-dependent effects of vatalanib on BN472 IFP and TVol. BN472 rat mammary carcinomas were established in female BN
rats as described in the Materials and Methods section. After 2 to 3 weeks of growth, rats were treated with vatalanib at the doses
shown (per os, daily), and IFP and TVol were determined on days 2 and 7. Results show the T/C on day 7 after treatment for IFP and TVol
(A) and the correlation between the two on day 7 (B).
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(Table 3). An alternative schedule of 75 mg/kg twice a week improved
the efficacy (T/CTVol day 7 = −0.16) and gave a similar effect on IFP after
2 to 3 days (T/CIFP = 0.59, P = .07). There was also a significant posi-
tive correlation between early IFP changes and the eventual change in
TVolday 7 (Figure 3D).
Thus, in general, for all three cytotoxics, a drug-induced decrease
in IFP was paralleled by decreases in TVol.
Drug-Induced Changes in IFP as an Early Marker of Response
As already described, significant linear correlations were seen for
patupilone, vatalanib, and gemcitabine in BN472 tumors between
early changes in IFP, that is, day 2 or 3 and the eventual change in
TVol on day 7 (Figure 3, A, B, and D). A similar observation was also
made for patupilone in the RIF-1 model (Figure 3C ), suggesting
some relationship between IFP and rTBV. Because the IFP changes
tended to occur before those in TVol, the correlations imply that IFP
could be used as an early marker of response. Interestingly, this effect
seemed stronger in the orthotopic tumor models. For example, for
patupilone, which was tested in two orthotopic and three ectopic mod-
els, significant correlations between early IFP changes and late TVol
changes were only seen in orthotopic tumors but not in the xenografts.
Finally, in the BN472 tumor, there was a trend for higher basal levels
of IFP to be associated with response to both low-dose patupilone (P =
.04) and vatalanib (P = .07), suggesting that pretreatment levels of IFP
might also have the potential be used to predict response (Figure 3, E
and F).
Table 3. Effect of Cytotoxics on the Growth and IFP of Several Tumor Models.
Drugs Dose (mg/kg), Once Tumor Host n Day 2/3 Day 6/7
T/CIFP T/CTVol T/CIFP
Patupilone 4 Human 1A9 Harlan nude mouse 24 0.47* 0.14† 0.18†
4 Human 1A9ptx10 24 0.55* 0.50‡ 0.37†
4 Human U87 8 1.2 0.37‡ 0.89
4 Murine RIF-1 C3H/He mouse 5 0.40* 0.24* 0.82
1.5 Rat BN472 BN rat 5 0.52† 0.06§ 0.32†
Gemcitabine 150 6 0.51§ 0.07* 1.18
CP 50 8 0.82 −0.2† 0.65§
150 Murine RIF-1 C3H/He mouse 6 0.78 0.06* 0.84
Tumor initiation is described in the Materials and Methods section; after 2 to 3 weeks of growth, IFP was determined before (day 0), during (day 2 or 3), and after treatment (day 6 or 7) with patupilone,
gemcitabine, or CP at the doses and schedules shown. Results show the effect of one dose for each drug in a specific tumor model as the T/C for TVol and IFP.
*P < .01, significantly different from the change in the vehicle.
†P < .001, significantly different from the change in the vehicle.
‡The T/C is low but not significantly different from the change in the vehicle (P < .3; 2-tailed t-test or one-way ANOVA with Tukey test post hoc).
§P < .05, significantly different from the change in the vehicle.
Figure 3. Correlations between IFP and tumor response to treatment. BN472 rat mammary carcinomas were established in female BN
rats (A, B, D–F) and RIF-1 tumors in C3H/He mice (C) were created as described in the Materials and Methods section. After 2 to 3 weeks
of growth, IFP was determined before (day 0), during (day 2 or 3), and after treatment (day 6 or 7) with patupilone (0.15-4 mg/kg once),
vatalanib (30-200 mg/kg daily) or gemcitabine (75 mg/kg twice weekly and 150 mg/kg once). Results show Pearson correlations for
individual tumors between IFP-F on days 2 to 3 and ΔTVol on days 6 to 7 for treatment with vatalanib (A) patupilone (B, C) or gemcitabine
(D) and between the response of individual tumors (ΔTVol) and the pretreatment basal IFP for rats treated with 0.3 mg/kg patupilone
once (E) or 100 mg/kg vatalanib daily (F).
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Discussion
The basal IFP has previously been shown to be dependent on the type
of tumor and the host [21]. We have also investigated this phenomenon
by comparing four different tumors in different backgrounds and sites
within the host. Our data suggest that the implantation site has no ef-
fect on the basal IFP of rat BN472 or murine B16/BL6 tumors (ID or
intramammary vs SC) or on rat C6 tumors grown in different nudemice
(Harlan vs BALB/c). However, when the rat PROb tumor was grown
inHarlan nudemice (both SC), there was a significantly lower IFP com-
pared with the same tumor in BDIX rats (10.5 vs 15.2mmHg). Indeed,
in general, rat tumors tended to have a higher IFP. Tumor IFP is depen-
dent on many factors, including vessel permeability and flow [1,2], and
perhaps also rTBV because we have recently found that rat tumors
have a greater rTBV and permeability compared with the same tumors
grown in mice [22]. These observations support the concept that IFP is
strongly affected by the host vasculature and, in particular, the rTBV.
Furthermore, we found in both untreated rat BN472 and PROb tumors
that basal IFP was significantly positively correlated with basal rTBV.
This correlation was weaker for BFI because it was only observed in
one of the two models, which may reflect the fact that this parameter
could not be so accurately measured by the DCE-MRI method that
we have used (see Materials and Methods section).
To further investigate the nature of tumor IFP, we studied the effect
of seven different chemotherapeutics (four cytostatics and three cyto-
toxics) on IFP. All seven agents were able to reduce IFP sooner (days 2
to 3) or later (days 6 to 7), but the magnitude of these effects was also
dependent on the type of tumor and, to a certain extent, the host.
Thus, imatinib reduced the IFP of PROb tumors in rats by 20% to
30% and significantly inhibited growth but caused a much greater de-
crease (−85%) when the same tumor was grown in nude mice, despite
a lack of effect on tumor growth in the latter model. In the rat model,
there was no evidence that an IFP decrease was associated with changes
in vasculature in volume, flow, or hypoxia. Vatalanib also strongly in-
hibited PROb growth in rats but had minimal effect on IFP. In con-
trast, vatalanib dose-dependently inhibited growth and IFP of rat
BN472 tumors. In this model, there was clear evidence of a relation-
ship between changes in IFP and tumor vasculature, with decreases
in IFP correlating with decreases in rTBV and a trend for a decrease
in blood vessel width. The hypothesis of Jain [23] predicted, and pro-
vided evidence, that pruning of the vasculature by antiangiogenics
would lead to narrower vessels, with decreased density and permeabil-
ity and thus a lower IFP with, in some cases, increased blood flow and
oxygenation. This seemed to be the case for vatalanib in BN472 tu-
mors: partial growth inhibition was associated with reduced IFP and
rTBV, and as we have previously reported, permeability was strongly
decreased in this model [17]. Thus, considering two rat models, in one
(vatalanib on BN472), an IFP decrease reflected tumor response and
vascular normalization, whereas in the other (imatinib on PROb), an
IFP decrease was apparently independent of vascular changes despite a
strong effect on tumor growth.
Two other cytostatics, everolimus and AEE788, also reduced BN472
IFP by 25% to 50%, but further comparisons with the vasculature were
not made. The data with these two drugs, however, confirmed that de-
creases in IFP paralleled inhibition of tumor growth.
The cytotoxic patupilone dose-dependently decreased the IFP of
BN472 tumors, and in comparison to the cytostatics and two other
cytotoxics (gemcitabine and CP) caused much greater decreases in IFP
of up to 70%. As previously reported [8], IFP decreases in this model
were strongly correlated to decreases in rTBVand increases in apoptosis.
Because IFP, in theory, reflects not only the vasculature but also high
tumor cell density around the blood vessels, the strong antivascular effect
and direct antitumor effect may account for the very large decreases in
IFP caused by patupilone in this well-vascularized model.
Others have reported that chemotherapeutics can reduce the IFP
of experimental tumors, for example, imatinib on PROb tumors [6],
dexamethasone [4], and an anti-VEGF monoclonal antibody [24] on
human tumor xenografts. IFP decreases have also been reported in
the clinic for bevacizumab [9] and paclitaxel [10] in rectal and breast
tumors, respectively. However, these decreases in IFP have not been
correlated with eventual response in the individual tumors. Using this
approach, we have shown that decreases in IFP that were detectable after
2 to 3 days, in most cases before a change in TVol was detectable, can
show a significant positive linear correlation (r2 = 0.23-0.56, P < .05)
with the eventual response as measured after 6 to 7 days. These data
suggest an important relationship between IFP and tumor response,
although it may not always be a linear relationship, and of course, other
factors dictate tumor response. Nevertheless, these data imply that a de-
crease in IFP could be used as an early marker of response in the clinic.
Interestingly, this was only apparent for the orthotopic tumors and,
except in one case (vatalanib on BN472), was limited to cytotoxics.
Given the evidence described previously for a relationship between
IFP and rTBV, this may be because of orthotopic tumors being better
Table 4. Summary of Correlations between IFP-F and ΔTVol.
Tumor Host Compound IFP-Fday 2/3 vs ΔTVolday 6/7 IFP-Fday 6/7 vs ΔTVolday 6/7
n r2 P n r2 P
Rat BN472 BN rat Patupilone 63 0.33 .0000008 64 0.18 .0004
Vatalanib 28 0.37 .0006 27 0.38 .0007
Gemcitabine 17 0.54 .026 17 0.009 .92
CP 16 0.13 .17 16 0.41 .008
AEE788 26 0.01 .6 26 0.005 .72
Everolimus 14 0.008 .77 14 0.09 .30
Rat PROb BDIX rat Imatinib 12 0.20 .14 12 0.07 .40
Harlan nude mouse 14 0.09 .30 14 0.10 .26
Murine RIF-1 C3H mouse CP 11 0.11 .32 11 0.04 .58
Patupilone 14 0.46 .005 14 0.09 .28
Human 1A9 Harlan nude mouse 50 0.04 .19 50 0.15 .005
Human 1A9ptx10 58 0.05 .08 58 0.01 .40
Human U87MG 22 0.002 .85 22 0.0004 .95
Data limited to models where the mean IFP-F was ≥ 0.70 and/or significantly affected with TVol data available at 6 to 7 days after initiation of treatment. Data in boldface emphasis show a significant
relationship (P < .05).
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vascularized than xenografts [12] and, because cytotoxics can kill both
tumor and endothelial cells, would therefore cause much larger de-
creases in IFP. The exception to this hypothesis was CP, which, although
showing strong a efficacy in two models, had weaker effects on IFP and
no significant correlations between early IFP-F and TVol. However, in
the RIF-1 model, CP increased rTBV, which should increase IFP and
thus counteract decreases in IFP resulting from tumor cell kill. This
observation underlines the relationship between tumor IFP and rTBV.
Furthermore, where IFP is not readily measurable in patients, alter-
native, entirely noninvasive measurements could be used instead to
measure rTBV or perhaps BFI, for example, DCE-MRI, ultrasound,
or Doppler.
Finally, there was evidence that the basal IFP in BN472 tumors,
and thus by implication rTBV, was related to response for both pa-
tupilone and vatalanib, that is, more vascularized tumors were more
likely to respond to treatment. Interestingly, this is consistent with
recent clinical data, which showed that renal cell carcinomas with
a higher permeability were more sensitive to the multitargeted cyto-
static sorafenib [25].
In conclusion, our data add to the accumulating literature that
tumor IFP is dependent on the host vasculature and, in particular,
the blood volume (rTBV) of the tumor. Treatment with cytotoxic
or cytostatic agents significantly decreased the IFP of ectopic and
orthotopic tumor models, and this paralleled the decreases in rTBV.
Rapid decreases in IFP preceded significant changes in tumor size,
and this seemed more prevalent in orthotopic models perhaps be-
cause these models are more vascularized than ectopic models. Our
data suggest an important potential clinical application of measuring
IFP, that is, that decreases in tumor IFP could be a generic marker of
response to therapy.
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